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Introduction
Moxidectin is a potent, broad-spectrum endectocide with
activity against a wide range of nematodes, insects and
acari. It is used worldwide as a parasiticide in a variety of
mammalian species including food-producing and
companion animals.
The first MOX-containing product was an injectable
formulation for cattle, approved for commercial use in
Argentina in 1989. Subsequent formulations introduced
worldwide for control of parasitosis include a tablet and
a sustained release injectable for prevention of heartworm
disease in dogs, injectable and oral drenches for sheep, a
pour-on formulation for cattle and deer, and sustained
release injectable formulations for cattle and sheep. These
long-acting formulations provided significantly longer
persistent activity than the earlier formulations, including
season-long control against some parasite species.
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Abstract
This article reviews the current knowledge of the use of moxidectin (MOX) in horses, including its
mode of action, pharmacokinetic and pharmacodynamic properties, efficacy, safety and resistance
profile.
Moxidectin is a second generation macrocyclic lactone (ML) with potent endectocide activity. It is
used for parasite control in horses in an oral gel formulation.The principal mode of action of MOX
and of other MLs is binding to gamma-aminobutyric (GABA) and glutamate-gated chloride
channels. Moxidectin is different from other MLs in that it is a poor substrate for P-glycoproteins
(P-gps) and therefore less susceptible to elimination from parasite cells through this mechanism.
Due to its unique physico-chemical and pharmacokinetic characteristics, MOX provides broad
distribution into tissues, long half-life, significant residual antiparasitic activity, and high efficacy
against encysted cyathostomin larvae. These characteristics allow for high efficacy and longer
treatment interval against all important nematodes, when compared to other equine anthelmintics.
A combination of MOX with praziquantel provides expanded spectrum of activity by adding activity
against cestodes.Appropriate use of MOX allows for the development of strategic anthelmintic pro-
grammes that are different from those with conventional anthelmintics. Fewer treatments are
required over a period of time, and therefore impose less frequent selection pressure for resistance.
Open Access
Combination products, including an injectable formu-
lation of MOX with clostridial and caseous lymphadenitis
vaccines for sheep, are commercially available in major
sheep producing countries. Additionally, an ongoing
collaboration between Wyeth/Fort Dodge Animal Health
and the World Health Organization led to the develop-
ment of an oral formulation of MOX for humans, which
is being evaluated in several African countries for preven-
tion of river blindness, a parasitic disease caused by
Onchocerca volvulus.
For horses, MOX is formulated as unique, easy-to-
administer oral gel formulation that provides excellent
and long-lasting efficacy against nematodes and gastro-
intestinal bots. A second gel formulation containing MOX
in combination with praziquantel adds efficacy against
cestodes.
Chemistry and pharmacology
Moxidectin is a semi-synthetic methoxime derivative of
LL F-2924α, commonly referred as F-alpha or nemadectin,
a 16-member pentacyclic lactone of the milbemycin class.
F-alpha is a product of fermentation of Streptomyces
cyaneogriseus subsp. noncyanogenus, a bacterial organism
isolated in 1983 from a sample of sand from Victoria,
Australia. F-alpha possesses strong anthelmintic activity
but has limited ectoparasiticide activity. Moxidectin is the
result of chemical optimization of F-alpha. Moxidectin
differs from ivermectin (IVM) by the absence of a
dissacharide moiety on carbon-13, a substituted olefinic
side chain at carbon 25 and a unique methoxime moiety
at carbon-23. Due to differences in chemistry and
biological activity compared to other MLs developed for
similar uses, MOX is classified as a second generation ML.
Studies to determine the mode of action of MLs on
parasites demonstrated that these compounds act by
binding to ligand-gated chloride channels, more speci-
fically the subtypes that are gamma-aminobutyric (GABA-
A) mediated and glutamate-gated [1]. The consequence of
ML binding and activation is an increased permeability,
leading to an influx of chloride ions and flaccid paralysis
of the parasite leading to death. Recent work identified a
dopamine-gated ion channel (HcGGR3) in Haemonchus
contortus that is associated with ML resistance [2].
A number of differences in the modes of action of aver-
mectins and milbemycins have been proposed for
ruminant parasites. One example is the difference in the
degree of pharyngeal pumping activity present in
Haemonchus contortus that has undergone selection with
IVM. In this selected strain of H. contortus, pharyngeal
pumping activity is altered in presence of IVM, but
unchanged in the presence of MOX, suggesting to some
extent a difference in mode of action [3]. Another
example is the degree of transport of MLs by p-glyco-
proteins (P-gp). P-gps are transmembrane pumps that
have been shown to reduce the uptake of lipophilic
compounds from the GI tract, to limit penetration into
tissues, including brain, and to enhance elimination by
biliary, intestinal or renal secretion. MOX is a poor
substrate for P-gps, compared to other MLs, such as IVM
and selamectin. This is demonstrated by the significantly
lower rate (p<0.01) of transport of radiolabeled MOX,
compared to radiolabeled IVM and selamectin, across
human intestinal epithelial cell monolayers and canine
peripheral lymphocyte membrane both from basal to
apical direction as well as from apical to basal direction [4].
The toxicity of MLs is believed to be dependent, in part,
on transport by P-gps [4,5]. P-glycoproteins act as trans-
port proteins able to carry certain drugs, including MLs,
across cell membranes. Over- or under-expression of
P-gps can lead to accumulation or depletion of a
compound within cells.
In the case of over-accumulation in cells of the nervous
system, signs of neurotoxicity may be seen, even when the
recommended commercial dose has been administered.
Investigations into the sensitivity of some collie-type dogs
to IVM have identified the presence of genetically based
P-gp deficiency which leads to neurotoxicity at doses
considered safe in the broader canine population.
Comparisons of the affinity of MLs for P-gps demon-
strated that MOX is a poor substrate for P-gps and differs
in this property by an order of magnitude from the
avermectins, such as IVM. This may explain the greater
mammalian safety of MOX compared to IVM, most
notably in P-gp deficient animals, such as some collie
dogs [6-8]. This property of MOX means the benefits of
monthly, or longer sustained release protection against
heartworm infection is available for dogs susceptible to
toxicity from IVM-based products [9].
The converse of P-gp deficiency, namely P-gp over-expres-
sion, is increasingly identified as being an important factor
in anthelmintic resistance in nematodes. A clinical
conundrum for many years has been why MOX is effective
in controlling IVM-resistant nematodes when both are
classified as MLs. The differing affinity for P-gps of MOX in
comparison with the avermectins may play an important
role. Selection on a P-gp gene has been identified in ML-
selected nematode strains [10]. However, quantitative and
qualitative differences have been identified between MOX
and IVM in this selection. Further studies of the P-gps lend
additional support to the importance of these transport
proteins in the development of resistance to MLs [11,12].
The disposition of MOX in horses is well described,
including its metabolic fate. Studies conducted with the
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use of radiolabeled MOX formulated as an oral gel
demonstrated that fecal excretion of the parent com-
pound was the main elimination pathway, accounting for
77% of the dose administered [13], thus confirming that
the product remains predominantly as the active parent
compound and is not extensively broken down to less
active metabolites.
Comparative pharmacokinetics of MOX and IVM after
oral administration to horses were also performed [14].
Horses were treated orally with a gel formulation at the
label dose of 0.4 mg of MOX per kg of body weight. Blood
was collected over time and plasma assayed by high
performance liquid chromatography with fluorescence
detection. Results showed MOX has a favorable pharmaco-
kinetic profile compared to IVM, including a longer
elimination half-life and greater area under the curve.
These are summarized in Table 1. The longer time course
of MOX in horses leads to a longer exposure of parasites
to MOX. This delivers a positive impact on efficacy as
demonstrated by the longer egg reappearance interval
following treatment and the high efficacy against stages of
parasites not readily controlled by other compounds. In
addition to plasma pharmacokinetics, another study
documented the residue profile of MOX in selected horse
tissues after oral administration of the commercial gel
formulation at the label dose [15]. Concentrations of
MOX in tissues are summarized in Table 2. As expected,
due to its lipid solubility, MOX was found at highest
levels in the abdominal and subcutaneous fat. This fat
depot naturally releases MOX into the systemic circula-
tion over time and contributes to the long half-life and
sustained activity. Conversely, little MOX was found in
lean tissues, such as muscle, supporting a short with-
holding period for meat. This is consistent with tissue
residue data from cattle [16] and sheep [17] confirming a
consistent metabolic and residue profile for MOX in
major domestic species.
Efficacy and safety
The efficacy of MOX for nematode control in horses is
well documented in controlled laboratory studies, field
efficacy studies and by years of use by veterinarians and
horse owners around the world. Typical study results are
reported by Cleale et al. in a multicenter evaluation of
pastured horses in 3 states of the United States, where 72
pastured horses were studied in Idaho, Illinois and
Tennessee [18]. Animals had an average age of 32, 32 and
18 months in Idaho, Illinois and Tennessee, respectively
and average pre-treatment fecal egg counts (EPG) of 266
(range 78-392), 108 (range 31-1042) and 576 (range 10-
2850) eggs in the same States. The horses were randomly
divided into 2 groups, one treated with MOX gel at the
label dose of 0.4 mg/kg orally and the other group left as
untreated control. Parasiticidal efficacy was determined
by necropsy and parasite count, conducted 12 to 14 days
after treatment. Horses were determined to have a mixed
infection of ascarids, small strongyles, large strongyles,
tapeworms and bots. As expected, no efficacy of MOX was
observed against the tapeworm Anoplocephala perfoliata.
For all other parasites encountered, including Gastero-
philus spp. larvae, adult and larval stages of ascarids and
large and small strongyles, efficacy was greater than 95%,
representing a significant difference from control
(p<0.05) as demonstrated in Tables 3 and 4, which
contains pooled data from all 3 geographical locations.
Other efficacy studies have demonstrated differences in
results following the treatment of cyathostomes by either
MOX or IVM. One such study was conducted on six horse
farms in Northwest Arkansas [19]. A total of 96 horses
that were scheduled for anthelmintic treatment were
randomly divided into 3 groups and treated with either
MOX (QUEST – Fort Dodge Animal Health, Overland
Park, KS, USA), IVM (EQVALAN – Merial Limited, Duluth,
GA, USA) or fenbendazole (FBZ) (PANACUR –
Intervet/Shering-Plough, Millsboro, DE, USA), according
to label directions. Evaluation of efficacy was performed
by fecal egg count tests comparing counts prior to
treatment, on Day 0, with FECs conducted on Days 56, 84
and 112 after treatment. On Day 0, FECs did not vary
across treatment groups, but significant differences were
seen across treatment groups on the post-treatment
evaluations, with superior efficacy of MOX, followed IVM
and FBZ (p<0.05), as demonstrated in Table 5. The results
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Table 1 - Comparative pharmacokinetics of moxidectin (MOX) and
ivermectin (IVM) after oral administration in horses expressed as mean
(± SD)
IVM MOX
Dose (mg/kg) 0.2 0.4
Cmax (μg/mL) 44.0 (± 23.1) 70.4 (± 10.7)
Tmax (day) 0.38 (± 0.24) 0.37 (± 0.19)
T1/2 elim (day) 4.25 (± 0.29) 23.11 (± 11.0)
AUC 0-t (μg/day/mL) 132.7 (± 47.3) 363.6 (± 66.0)
Cmax = Maximum concentration
Tmax = Time for maximum concentration
T1/2 = Terminal half-life
AUC = Area Under the concentration vs. time Curve
Table 2 - Tissue concentrations of moxidectin (MOX) after oral
administration of 0.4 mg/kg to horses.






ppb = parts per billion
of this study have great significance in the development of
strategic anthelmintic dosing programmes in that they
not only confirm the high efficacy of MOX against key
equine parasites, but also show that less frequent
anthelmintic treatments are needed if MOX is used for
cyathostome control.
While MOX may be used interchangeably with other
effective anthelmintics for broad spectrum control of
nematodes, it also has the potential to be used differently
by applying its known characteristics of high potency and
long duration of activity. Sustainable worm control
programmes can be designed that provide the same level
of protection from worms through fewer treatments, thus
reducing the selection pressure for resistance.
One of the significant differentiating factors of MOX from
other MLs is the efficacy against encysted stages of cyatho-
stomes, the causal agents of larval cyathostominosis. This
clinical syndrome is characterized by the simultaneous
emergence of larvae leading to significant inflammatory
enteropathy in the cecum and colon, and resulting in
colitis, weight loss, diarrhea and colic. The high efficacy of
MOX against inhibited stages of cyathostomins is well
documented in the published literature [20-22]. A
dilemma for clinicians in managing control of cyatho-
stomin infections is whether treatment with an
anthelmintic effective against luminal and developing
stages only, will trigger mass emergence of inhibited
stages with the associated clinical syndrome, or whether
treatment using larvicidal products will lead to a mass die
off of inhibited stages that may cause inflammatory
responses in the mucosa and colic. A recently published
study described the evaluation of the degree of inflam-
mation caused by the killing of encysted cyathostomins
larvae using either MOX or FBZ [23]. In that study, MOX
was administered orally once at 0.4 mg/kg, while FBZ was
administered daily for 5 days at the dose of 7.5 mg/kg.
Animals were then sacrificed and parasites recovered
14 days after treatment. While both compounds were
effective in removing larval cyathostomins, indicating a
strain that is susceptible to both compounds, there was a
significant difference in the degree of mucosal
inflammation associated with the larval kill. Histolo-
gically, in animals treated with FBZ, T-lymphocytes
accumulated around the intact larvae forming a granu-
loma along with eosinophils, with the inflammation
extending into the mucosa and being associated with
ulcerations. Conversely, in horses treated with MOX, mor-
phological alterations were not observed in histo-
pathology, and the disintegrated larvae resorbed without
causing severe inflammation in the gut wall. Based on the
safety and efficacy profile demonstrated for MOX, the
clinician has available the means to control all stages of
cyathostomins without the necessity to adjust from a
normal dose or to administer repeated treatments, and
without inducing severe inflammatory responses.
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Table 3 - Geometric means of egg counts and percent efficacy of
moxidectin (MOX) against non-cyathostomins, compared to control
Geometric means
control MOX Percent Efficacy
Anoplocephala perfoliata 4.56 2.58 43.3
Gasterophilus intestinalis 2nd instar 16.19 0.66* 95.5
Gasterophilus intestinalis 3rd instar 68.1 2.75* 96.0
Gasterophilus nasalis 2nd instar 2.24 0.00* 100.0
Gasterophilus nasalis 3rd instar 5.27 0.02* 99.6
Oxyuris equi L4 8.39 0.31* 96.3
Parascaris equorum adult 1.78 0.07* 96.3
Parascaris equorum L4 1.02 0.00* 100.0
Strongylus edentatus adults 2.41 0.03* 98.7
Strongylus vulgaris adults 5.27 0.21* 96.1
Triodontophorus brevicaudata adults 9.49 0.00* 100.0
Triodontophorus serratus adults 22.04 0.00* 100.0
* significant difference from control (p<0.05)
Table 4 - Geometric means of egg counts and percent efficacy of
moxidectin (MOX) against cyathostomins, compared to control
Geometric means
Control MOX Percent Efficacy
Coronocyclus coronatus 205.06 0.07* 99.97
Coronocyclus labiatus 126.98 0.00* 100
Coronocyclus labratus 403.12 0.09* 99.98
Cyathostomum catinatum 3917.4 0.00* 100
Cyathostomum pateratum 128.89 0.00* 100
Cylicocyclus brevicapsulatus 9.41 0.00* 100
Cylicocyclus elongatus 8.59 0.00* 100
Cylicocyclus insigne 134.65 0.18* 99.86
Cylicocyclus leptostomum 935.71 0.00* 100
Cylicocyclus nassatus 5073.92 0.09* >99.99
Cylicocyclus radiatus 46.45 0.09* 99.81
Cylicostephanus calicatus 1080.56 0.09* 99.99
Cylicostephanus goldi 113.53 0.00* 100
Cylicostephanus longibursatus 7518.56 0.09* >99.99
Cylicostephanus minutus 5585.9 0.66* 99.99
Petrovinema poculatus 18.89 0.00* 100
Poteriostomum imparidentatum 3.69 0.00* 100
Luminal cyathostominL4 3726.11 21.60* 99.42
* significant difference from control (p<0.05)




Moxidectin 99.1 97.6 94.9
Ivermectin 85.9 24.2 -8.1
Fenbendazole 16.4 -27.0 -32.0
The use of MOX in pregnant mares was demonstrated to
be safe in studies conducted during the registration phase
of the gel formulation [24]. In addition a study was
conducted to explore the impact of a strategic MOX
treatment of perinatal mares on worm control in their
foals [25]. In that study, a group of 25 pregnant mares was
divided into 2 groups with 12 being treated with MOX
oral gel at the label dose around the time of foaling, and
13 were left as untreated controls. Foals were born from
Day -1 to Day 76. Based on coproculture and pasture
analysis, the nematode challenge was predominantly of
Cyathostomum spp. Complete control of parasites,
including Strongyloides westeri, was maintained for at least
91 days in the mares and in the foals born from mares
that were treated with MOX. In this study, the parasite
challenge in the mares was significant, and the control
mares had to be treated with IVM on grounds of welfare.
At the end of the grazing period, the foals born from
mares treated with MOX had an average body weight
17 kg higher than those born from mares that were
treated with IVM (control mares) despite the fact that
their foals were themselves treated with IVM at the age of
3 months. The potential of using MOX in perinatal mares
to control nematode infections in foals warrants further
investigation.
The potential of tapeworms to induce colic in horses has
been documented [26-28] and combining MOX with the
potent cestocide praziquantel allows simultaneous
treatment of roundworms and tapeworms in a single
application. The efficacy and safety of this combination
product was demonstrated in a large field evaluation
where four hundred client-owned horses were treated
with either the combination of MOX + praziquantel or
control. In that study, no adverse event was observed and
a reduction of over 99% of Anoplocephala spp. and over
98% reduction in strongyle egg counts was observed [29].
Other less prevalent tapeworms, such as Anoplocephala
magna and Paranoplocephala mamillana, are also known to
have clinical significance in the horse [30]. Efficacy
studies conducted on horses naturally infected with
cestodes that were divided into matching treated and
untreated groups demonstrated, at necropsy, the
complete efficacy of the combination of MOX plus
praziquantel against these tapeworms [31].
Another differentiating feature of MOX compared to
other MLs is the environmental profile, most notably the
low impact of MOX residues in faeces on the emergence
rate of dung beetles in contrast to the findings with
avermectins [32]. This was demonstrated in evaluation of
the rate of emergence of the dung beetle Aphodius constans
exposed to feces of horses treated orally with the
combination of MOX and praziquantel [33]. Dung
beetles play an important role in parasite control by
providing rapid dispersal and/or burial of dung and
therefore reducing the habitat for nematode eggs and
larvae, in addition to providing improvement in pasture.
Concerns about the potential development of resistance
to MLs have been debated in the equine parasitology
community for some years [34,35]. Increasing concerns
have arisen with recent reports of the inefficacy of MLs,
both IVM and MOX against Parascaris equorum. Such
failures were reported initially from the Netherlands [36],
later from North America [37-39], then other European
countries [40-42] and most recently Brazil [43]. Fre-
quency of anthelmintic treatments has been cited as a
major contributing factor for selection for resistance by
many parasitologists, and a review of common nematode
control practices in horses indicates the highest frequency
of treatments is in foals, specifically for the control of
ascarids. Hence, the appearance of resistance under these
conditions is not surprising, also taking into account that
the initial efficacies of MLs against P. equorum indicated
this was a dose-limiting species for this group of
compounds. The reduced efficacy of anthelmintics in
young versus adult horses has been long recognized [44].
Further concerns on the development of ML resistance are
related to the reported reduction in the egg reappearance
period (ERP) of cyathostomins following IVM treatment
[45]. This is taken as a first sign of reduced sensitivity of
cyathostomins to IVM.
The complexity of the mechanisms of resistance to MLs
and our incomplete understanding of them has led to
varied and different proposals for the best way of
minimizing selection for resistance and preserving the
efficacy of MLs for as long as possible. Factors to consider
include optimal treatment frequency; should the less
potent compound, IVM, be used until it is ineffective,
then MOX used to control these parasites; what role as
“refugia” is played by inhibited stages that are not effec-
tively controlled by IVM, but against which MOX has high
potency; and is there a link between benzimidazole resis-
tance and ML resistance as selection has been shown at
the beta-tubulin site for both classes of compounds [46].
One aspect on which there is general agreement is that
anthelmintic treatments should be used only when
needed, and recommendations have been made to
monitor faecal egg counts and treat individual horses
only when needed. A consensus on the appropriate
threshold for treatment has not been reached but is of the
order of 150-200 eggs per gram. The extended egg
reappearance interval for MOX means the same level of
control can be obtained with fewer treatments than with
IVM [47-49]. The issue of the impact of treating inhibited
cyathostomes has led to heated debate. The point is moot
if horses are treated in the absence of these inhibited
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stages. Ivermectin does not deliver effective control of
these stages [50,51] even at elevated doses [52], however
efficacies of the order of 35% to 77% [53] have been
reported. Therefore, characterizing such populations as
“unexposed and unselected refugia” is both simplistic and
incorrect, survivors of the exposure to IVM are able to
mature and contribute eggs to the next generation. In
contrast, the high efficacy of MOX against all mucosal
stages [22,54] leaves few survivors and the contribution of
resistance alleles to the next generation is much reduced.
Taking into account the current knowledge of rates of
selection for resistance in nematodes [55] and the
quantitative and qualitative differences in mechanisms of
action of resistance, it is strongly recommended that MOX
be used strategically as a first line treatment in equine
nematode control programmes, and not “saved” for
dealing with IVM resistant strains. Although MOX has
been shown to control many IVM resistant parasites once
resistance to therapeutic levels of IVM has been
recognized [56-59] it is likely that the first steps have been
taken towards MOX resistance [60-62]. Research
continues to elucidate the similarities and differences in
IVM and MOX resistance, particularly in relation to P-gps,
Multi-drug Resistance Proteins (MRPs) and ABC Trans-
porters [3-5,10-12]. “This new data in a parasitic nema-
tode confirms previous evidence obtained in C. elegans
that MOX has markedly different and less effect on
causing overexpression of both P-gps and MRPs in
nematodes compared with IVM. As P-gps and MRPs are
involved in the efflux of xenobiotics, their overexpression
appears to be a major mechanism of IVM resistance that
is not shared, or not shared to the same extent by MOX
selection.” [63]
Specifically in relation to equines, the presence of at least
two P-gp genes has been confirmed in PCR studies con-
ducted in nine different species of cyathostomins [64].
The best uses of MOX will be strategic and pre-emptive
use before any ML resistance.
Conclusion
Moxidectin provides safe and effective means of parasite
control for horses. As a second-generation ML, it has
different chemical, pharmacokinetic and pharmaco-
dynamic characteristics than the first generation MLs, the
avermectins, such as higher potency, longer half-life and
better diffusion into relevant tissues such as intestinal
mucosa. Moxidectin has the longest ‘egg reappearance
period’ after treatment, requiring fewer treatments over a
period of time for the same level of control of parasites.
This is important, as fewer treatments represent less
opportunities for development of nematode resistance, as
selection pressure is applied fewer times, compared to
other anthelmintic treatments. Through the application
of the known scientific differences unique to MOX we can
develop strategic worm control programmes different
from those with conventional anthelmintics. An example
is the perinatal treatment of mares that can be a viable
option to reduce worm transmission to their foals, and to
prevent the buildup of infective larvae on foaling
pastures. Moxidectin can be used as a conventional
anthelmintic in horses but also provides great flexibility
and convenience for treatment of important parasitosis in
horses, regardless of age or pregnancy status.
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